Two of the last ten came late. The 2019 accounts came in latest, 31 days after the end of the period.
Checked score
Checked score
The higher the Checked score (0 to 100), the smaller the chance that the company goes bankrupt within twelve months. That chance sets the band, from Critical to Excellent, and within the band how the company does against its sector peers counts too. With a low score, agree a shorter payment term, an advance or security.
XXVisible after signing in
HiddenVisible after signing in
Bankruptcy probability within 12 months
Bankruptcy probability
It is the chance that the company goes bankrupt within twelve months, estimated from the registers, the annual accounts and the Belgian Official Gazette. At 0.2%, about 2 in 1,000 comparable companies go bankrupt. The higher it is, the shorter the payment term to agree.
XXVisible after signing in
Financial strength
Financial strength
Financial strength measures the balance sheet and the results with three figures out of 100 from the latest annual accounts: solvency, liquidity and profitability. It does not directly set the Checked score's band. How the company does against its sector peers on these and on growth does count for its place within the band.
XXVisible after signing in
XXVisible after signing in
XXVisible after signing in
Score breakdown
Visible after signing inVisible after signing in
Credit verdict
Credit verdict
The credit verdict says how much credit you can give the company on open account. “Acceptable” means normal terms, “With conditions” means limiting the amount or the term. “Not advised” means asking for payment up front.
Visible after signing inVisible after signing in
Credit check for an amount and term of your choice
Name after signing inVisible after signing in changes role from director, formerly manager to director
Discharge granted to Name hiddenVisible after signing in · General meeting of 21-12-2023 · Gazette deed
Registered office moved from Galmaarden to Brussels
The registered office moved from Oulstbergstraat 8, 1570 Galmaarden to Dikkebeuklaan 115 bus 10, 1020 Brussel · Gazette deed
Incorporation
Founding capital of €18,600, 100 shares · Founded by Hidden nameVisible after signing in · Name after signing inVisible after signing in appointed as manager · published on 18-06-2009 · Gazette deed
First establishment
At the time the registered office was still in Galmaarden, Oulstbergstraat 8.
Sector peers are the companies with the same activity (NACE code) and, where stated, the same size, that the company is compared with. A percentile says how many of them do worse.
These companies have the same main activity as PAEME pharma: business and other management consultancy (NACE 70200). They are comparable in size and age: total assets between €499,000 and €735,000, founded between 2007 and 2010.
According to the KBO register, the main activity is business and other management consultancy (NACE 70200).
What is the legal form of PAEME pharma?
PAEME pharma is a private limited company (BV).
When was PAEME pharma founded?
PAEME pharma was founded on 16-06-2009.
Is PAEME pharma still active?
Yes, PAEME pharma is an active enterprise in the KBO register.
What is the turnover of PAEME pharma?
The turnover in financial year 2025 is about €82,000. This figure is estimated from the gross margin of €19,477 and 92 comparable companies (NACE 70200). It probably lies between €39,000 and €210,000. It is a rough estimate.Financials
Is PAEME pharma profitable?
In financial year 2025, PAEME pharma made a profit of €9,150.
Where can I find the annual accounts of PAEME pharma?
PAEME pharma filed 16 annual accounts with the National Bank of Belgium, the latest for financial year 2025.
When are the next annual accounts of PAEME pharma due?
PAEME pharma must file the annual accounts for financial year 2026 by 31-07-2027.Timeline